Nepuvibart - CAS 2640224-48-0

Nepuvibart (ZRC3308-B10), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, exhibits strong binding affinity to a distinct non-competing epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When combined in a 1:1 ratio with ZRC3308-A7, Nepuvibart is effective in preventing COVID-19 and in treating the early stages of the disease before it progresses to severe illness [1].

SARS-CoV

Microbiology/Virology

2640176

-20°C

Ice Packs

Inhibitory Antibodies